References
Morel A, Boisdron-Celle M, Fey L et al (2006) Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 5:2895–04
Amstutz U, Froehlich TK, Largiadèr CR (2011) Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 12:1321–1336
Van Kuilenburg ABP (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40:939–950
Caudle KE, Thorn CF, Klein TE et al (2013) Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther 94:640–645
Acknowledgments
We are grateful to Christine Pivot (Services Pharmaceutiques, Groupement Hospitalier Edouard Herriot, Hospices Civils de Lyon, Lyon, France) for her support and advice.
Conflict of interest
Authors reported none.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dhelens, C., Bonadona, A., Thomas, F. et al. Lethal 5-fluorouracil toxicity in a colorectal patient with severe dihydropyrimidine dehydrogenase (DPD) deficiency. Int J Colorectal Dis 31, 699–701 (2016). https://doi.org/10.1007/s00384-015-2191-0
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00384-015-2191-0